ASCO: Afatinib Prolongs PFS among EGFR-Mutation-Positive Lung Cancer Patients

Share this content:

(CHICAGO, IL) – Afatinib significantly prolongs progression-free survival (PFS) among EGFR-mutation-positive lung cancer, compared to pemetrexed plus cisplatin, according to an analysis of the LUX-Lung3 study presented at the 2012 American Society of Clinical Oncology Annual Meeting.

Afatinib is a selective, irreversible ErbB blocker of EGFR (ErbB1), HER2 (ErbB2) and ErbB4. Patients were tested for EGFR mutations and randomized 2:1 to receive afatinib (40mg daily; n=230) or intravenous pemetrexed (500mg/m2) plus cisplatin (75mg/m2) daily for up to six 21-day cycles (n=115). Baseline characteristics were well-balanced between the 2 study arms, reported lead author James Chih-Hsin Yang, MD, National Taiwan University Hospital, Taipei, Taiwan.

Afatinib was associated with a significantly longer median PFS than pemetrexed/cisplatin (11.1 vs. 6.9 months; HR=0.58; P=0.0004). Among 308 patients with common Dell9/L858R mutations, median PFS among afatinib patients was even longer (13.6 vs. 6.9 months for pemetrexed + cisplatin; HR=0.47; P<0.0001). Afatinib was also associated with a higher objective response rate (56% vs. 23%; P<0.0001) and longer delays in time to deterioration of cancer-related cough (HR=0.60; P=0.0072) and dyspnea (HR=0.688; P=0.0145).

Afatinib-associated toxicities included diarrhea (95%), rash (62%), paronychia (57%), and dry skin (29.3%), Dr. Yang reported. Drug-related adverse event discontinuations occurred in 8% of afatinib-arm patients and 11.7% of pemetrexed/cisplatin-arm patients.  

“Almost 50% of afatinib patients had drug-related adverse events of grade 3 or higher, but we must note that the median follow-up was 16 cycles vs. only 6 cycles for chemotherapy, so there was a longer period to detect AEs,” Dr. Yang noted.

All health-related quality of life measures trended toward favoring afatinib. Overall survival rate analysis should be possible in 18 to 24 months, Dr. Yang said.  

LUX-Lung 3 is the largest prospective trial to date, of EGFR mutation-positive lung cancer, and is the first study using pemetrexed/cisplatin as a comparator.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs